Active ingredients: avelumab
What it is used for
BAVENCIO is indicated for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC). This indication is approved based on tumour response rate, duration of response in a single arm study.,BAVENCIO is indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.,BAVENCIO in combination with axitinib is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Clear, colourless to slightly yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient avelumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.